Skip to main content
SUNFLOWER PHARMACEUTICAL GROUP CO.,LTD logo

SUNFLOWER PHARMACEUTICAL GROUP CO.,LTD — Investor Relations & Filings

Ticker · 002737 ISIN · CNE100001WT7 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,264 across all filing types
Latest filing 2026-06-05 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 002737

About SUNFLOWER PHARMACEUTICAL GROUP CO.,LTD

https://www.kuihuayaoye.com

Sunflower Pharmaceutical Group Co., Ltd. focuses on the research, development, manufacturing, and distribution of proprietary Chinese medicines, chemical drugs, and health supplements. The organization is particularly noted for its specialization in pediatric medicine, marketed under the "Little Sunflower" brand, which includes treatments for respiratory and digestive ailments. Its extensive product portfolio also covers gynecological health and general internal medicine. The group operates several integrated production bases and research institutes, facilitating a comprehensive approach to drug formulation and quality control. By leveraging a robust supply chain and a wide-reaching distribution network, the company provides a diverse range of over-the-counter and prescription solutions aimed at improving family health and wellness.

Recent filings

Filing Released Lang Actions
关于使用闲置自有资金进行现金管理的进展公告
Regulatory Filings Classification · 80% confidence The document is a regulatory announcement (‘公告’) by 葵花药业 (code 002737) reporting on the progress of using idle funds for cash management (purchasing wealth management products), detailing amounts, counterparties, yields, and risk controls. It is not a financial results release, an annual or interim report, nor does it involve share issuance, dividends, board changes, or M&A. It fits the catch-all Regulatory Filings category for miscellaneous compliance disclosures.
2026-06-05 Chinese
关于盐酸氨溴索口服溶液申请注册上市许可获得受理的公告
Regulatory Filings Classification · 85% confidence The document is an announcement by a pharmaceutical company regarding the acceptance of its drug registration application by the national drug regulatory authority. It contains no financial results, management changes, or meeting materials but constitutes a compliance/regulatory notice. This fits the “Regulatory Filings” fallback category for miscellaneous regulatory announcements (RNS).
2026-06-04 Chinese
2025年年度股东会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is an announcement by 葵花药业集团股份有限公司 detailing the convening of its 2025 annual general meeting, attendance statistics, each resolution proposed, and the precise voting results (number of shares for, against, abstained). It contains full disclosure of shareholder voting outcomes. This matches the definition of Declaration of Voting Results & Voting Rights Announcements (DVA).
2026-05-22 Chinese
关于注销全资子公司的进展公告
Regulatory Filings Classification · 75% confidence The document is a corporate announcement updating on the deregistration (注销) of a wholly-owned subsidiary, with no financial statements or voting results, not a management change, financing update, or securities transaction. It is a miscellaneous regulatory update, so it falls under Regulatory Filings (RNS).
2026-05-19 Chinese
关于参加黑龙江辖区上市公司2026年投资者网上集体接待日活动的公告
Investor Presentation Classification · 90% confidence The document is an announcement about the company's participation in an investor online collective reception day event. It mentions the date and time of the event and that company directors and executives will communicate with investors about various topics including 2025 annual performance, governance, strategy, financing plans, and sustainability. The document is short (520 characters) and does not contain any financial statements or detailed financial data. It is not a report itself but an announcement of an event for investor communication. Therefore, it fits best under Investor Presentation (IP) as it is a detailed presentation for investors focusing on financials, strategy, and market position, albeit in an event format rather than a document. Confidence is high due to clear description of investor communication event.
2026-05-08 Chinese
关于独立董事独立性自查情况的专项报告
Governance Information Classification · 82% confidence The document is a special report by the board evaluating the independence of the company’s independent directors, referencing listing rule requirements and self-regulatory guidelines. It is not announcing a board change, vote result, financial results, nor is it a simple report publication notice. Instead, it details the company’s governance practices around director independence, fitting the Governance Information category.
2026-04-26 Chinese

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.